Factors influencing participation in preventive interventions for gastric cancer: the results from the GISTAR study.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
15
9
2021
medline:
20
4
2022
entrez:
14
9
2021
Statut:
ppublish
Résumé
Search-and-treat strategy for Helicobacter pylori and surveillance of patients with precancerous lesions are recommended to decrease the burden of gastric cancer in high-risk areas. We aimed to evaluate the acceptance of the target population to these strategies. We applied a search-and-treat strategy combined with biomarker screening (pepsinogens I and II, gastrin-17) for atrophic gastritis to healthy individuals aged 40-64 years within the GISTAR Pilot study. Different means of invitation were evaluated - direct telephone calls, letters of invitation via the general practitioners. Participants with altered biomarker results were invited to undergo upper gastrointestinal endoscopy. H.pylori positive individuals were offered eradication therapy. Data on the compliance to the treatment and reasons for noncompliance were collected via telephone. Altogether 3453 participants were enrolled. The attendance of women participants was 1.9 times higher although active invitation strategies were mainly targeting men. The yield for the telephone invitations was higher than for mail-delivered invitations (2.1 calls vs. 7.7 letters required to recruit one study subject). Out of 661 individuals reached with the invitation to undergo upper endoscopy, 520 (78.7%) attended the procedure. Out of 1185 study subjects eligible for eradication, 810 (68.4%) accepted it. Of those having received the medication, 765(94.4%) completed it. The reasons for nonparticipation were the overall misconception of the importance of screening, busy schedule and others. While only the minority of the target population participated in the gastric cancer prevention strategy, relatively high compliance was seen among the participants. The acceptance rate and the identified reasons for refusing to participate in our study indicate that there is a need to raise gastric cancer awareness and its existent preventive strategies within the general population for their successful implementation in the community.
Identifiants
pubmed: 34519690
doi: 10.1097/CEJ.0000000000000682
pii: 00008469-202203000-00003
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02047994']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-136Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Asaka M, Kato M, Sakamoto N (Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol (2014). 49:1–8.
Aubin-Auger I, Mercier A, Lebeau JP, Baumann L, Peremans L, Van Royen P (Obstacles to colorectal screening in general practice: a qualitative study of GPs and patients. Fam Pract (2011). 28:670–676.
Blom J, Yin L, Lidén A, Dolk A, Jeppsson B, Påhlman L, et al. (Toward understanding nonparticipation in sigmoidoscopy screening for colorectal cancer. Int J Cancer (2008). 122:1618–1623.
Bornschein J, Leja M, Kupcinskas J, Link A, Weaver J, Rugge M, Malfertheiner P (Molecular diagnostics in gastric cancer. Front Biosci (Landmark Ed) (2014). 19:312–338.
Costa S, Barberis N, Larcan R, Cuzzocrea F (The incremental role of trait emotional intelligence on perceived cervical screening barriers. Psychol Health Med (2018). 23:880–890.
Firmino-Machado J, Varela S, Mendes R, Moreira A, Lunet NSCAN-Cervical Cancer collaborators. (A 3-step intervention to improve adherence to cervical cancer screening: the SCAN randomized controlled trial. Prev Med (2019). 123:250–261.
Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al.; Second Asia-Pacific Conference. (Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009). 24:1587–1600.
Graham DY (Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics (2020). 9:671.
Graham DY, El-Serag HB (European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut (2021). 70:1–2.
Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson N (Lost in knowledge translation: time for a map? J Contin Educ Health Prof (2006). 26:13–24.
Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O (Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q (2004). 82:581–629.
Herrero R, Parsonnet J, Greenberg ER (Prevention of gastric cancer. JAMA (2014). 312:1197–1198.
Kawar LN (Barriers to breast cancer screening participation among Jordanian and Palestinian American women. Eur J Oncol Nurs (2013). 17:88–94.
Lasser KE, Ayanian JZ, Fletcher RH, Good MJ (Barriers to colorectal cancer screening in community health centers: a qualitative study. BMC Family Pract (2008). 9:15.
Leja M, Dumpis U (What would the screen-and-treat strategy for Helicobacter pylori mean in terms of antibiotic consumption? Dig Dis Sci (2020). 65:1632–1642.
Leja M, You W, Camargo MC, Saito H (Implementation of gastric cancer screening - the global experience. Best Pract Res Clin Gastroenterol (2014). 28:1093–1106.
Leja M, Park JY, Murillo R, Liepniece-Karele I, Isajevs S, Kikuste I, et al. (Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open (2017). 7:e016999.
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al.; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). (Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut (2020). 69:2093–2112.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al.; European Helicobacter and Microbiota Study Group and Consensus panel. (Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut (2017). 66:6–30.
Momenimovahed Z, Tiznobaik A, Taheri S, Hassanipour S, Salehiniya H (A review of barriers and facilitators to mammography in Asian women. Ecancermedicalscience (2020). 14:1146.
Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al.; Hp-EuReg Investigators. (European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut (2021). 70:40–54.
O’Hara J, McPhee C, Dodson S, Cooper A, Wildey C, Hawkins M, et al. (Barriers to breast cancer screening among diverse cultural groups in Melbourne, Australia. Int J Environ Res Public Health (2018). 15:1677.
Park JY, Polaka I, Parshutin S, Kikuste I, Isajevs S, Santare D, et al. (Trial profile: pilot study of the multicentre randomised trial of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality (the GISTAR Pilot study). Microb Health Dis (2019). 1:e165.
Pimentel-Nunes P, Libanio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. (Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy (2019). 51:365–388.
Santare D, Kojalo I, Huttunen T, Rikacovs S, Rucevskis P, Boka V, Leja M (Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol (2015). 27:536–543.
Selva A, Torà N, Pascual E, Espinàs JA, Baré M (Effectiveness of a brief phone intervention to increase participation in a population-based colorectal cancer screening programme: a randomized controlled trial. Colorectal Dis (2019). 21:1120–1129.
Sugano K (Strategies for prevention of gastric cancer: progress from mass eradication trials. Dig Dis (2016). 34:500–504.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al.; faculty members of Kyoto Global Consensus Conference. (Kyoto global consensus report on Helicobacter pylori gastritis. Gut (2015). 64:1353–1367.
Tepeš B, Štabuc B (Slovenian society for gastroenterology and hepatology guidelines on the management of Helicobacter pylori infection. Zdrav Vestn (2011). 80:647–656.
van Dam L, Korfage IJ, Kuipers EJ, Hol L, van Roon AH, Reijerink JC, et al. (What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy? Eur J Cancer (2013). 49:2321–2330.
von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. (European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy (2013). 45:51–59.
World Health Organization (A guide to implementation research in the prevention and control of noncommunicable diseases. (2016). https://www.who.int/ncds/governance/policies/NCD_MSA_plans/en/ . [Accessed 07/03/2019].